Nivolumab Combination Improves Outcomes In Older Advanced Hodgkin’s Lymphoma Patients
From the 65th American Society of Hematology Annual Meeting:
Switching from brentuximab vedotin to nivolumab alongside chemotherapy increased progression-free survival and reduced toxicity in patients aged 60 years and older with classic Hodgkin’s lymphoma